Compare IPCA Labs with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs LUPIN - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS LUPIN IPCA LABS/
LUPIN
 
P/E (TTM) x 22.9 48.7 47.0% View Chart
P/BV x 4.4 2.5 177.8% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   LUPIN
EQUITY SHARE DATA
    IPCA LABS
Mar-18
LUPIN
Mar-19
IPCA LABS/
LUPIN
5-Yr Chart
Click to enlarge
High Rs695986 70.5%   
Low Rs400720 55.5%   
Sales per share (Unadj.) Rs260.2369.5 70.4%  
Earnings per share (Unadj.) Rs19.013.4 141.5%  
Cash flow per share (Unadj.) Rs33.137.4 88.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.0303.7 70.1%  
Shares outstanding (eoy) m126.20452.49 27.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.12.3 91.2%   
Avg P/E ratio x28.963.6 45.4%  
P/CF ratio (eoy) x16.622.8 72.6%  
Price / Book Value ratio x2.62.8 91.5%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,120386,064 17.9%   
No. of employees `00013.317.7 74.9%   
Total wages/salary Rs m7,35931,513 23.4%   
Avg. sales/employee Rs Th2,477.49,453.8 26.2%   
Avg. wages/employee Rs Th555.21,782.0 31.2%   
Avg. net profit/employee Rs Th180.6343.0 52.7%   
INCOME DATA
Net Sales Rs m32,836167,182 19.6%  
Other income Rs m4183,640 11.5%   
Total revenues Rs m33,254170,822 19.5%   
Gross profit Rs m4,50528,822 15.6%  
Depreciation Rs m1,77710,850 16.4%   
Interest Rs m2403,078 7.8%   
Profit before tax Rs m2,90518,534 15.7%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m5119,017 5.7%   
Profit after tax Rs m2,3946,066 39.5%  
Gross profit margin %13.717.2 79.6%  
Effective tax rate %17.648.7 36.2%   
Net profit margin %7.33.6 201.0%  
BALANCE SHEET DATA
Current assets Rs m19,455138,536 14.0%   
Current liabilities Rs m10,07661,299 16.4%   
Net working cap to sales %28.646.2 61.8%  
Current ratio x1.92.3 85.4%  
Inventory Days Days9884 116.9%  
Debtors Days Days67112 59.5%  
Net fixed assets Rs m20,260127,516 15.9%   
Share capital Rs m252905 27.9%   
"Free" reserves Rs m26,633136,517 19.5%   
Net worth Rs m26,886137,422 19.6%   
Long term debt Rs m2,34066,417 3.5%   
Total assets Rs m41,173279,494 14.7%  
Interest coverage x13.17.0 186.5%   
Debt to equity ratio x0.10.5 18.0%  
Sales to assets ratio x0.80.6 133.3%   
Return on assets %6.43.3 195.6%  
Return on equity %8.94.4 201.8%  
Return on capital %10.88.9 120.8%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64259,414 26.3%   
Fx outflow Rs m4,88422,282 21.9%   
Net fx Rs m10,75937,132 29.0%   
CASH FLOW
From Operations Rs m3,41116,660 20.5%  
From Investments Rs m-1,354-32,825 4.1%  
From Financial Activity Rs m-1,3047,441 -17.5%  
Net Cashflow Rs m753-8,724 -8.6%  

Share Holding

Indian Promoters % 45.9 46.6 98.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.4 11.3 100.9%  
FIIs % 25.3 31.9 79.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.1 172.3%  
Shareholders   36,892 98,259 37.5%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   TTK HEALTHCARE  UNICHEM LAB  DR. REDDYS LAB  ELDER PHARMA  ALEMBIC LTD  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 18, 2019 03:33 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - LUPIN COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS